康惠制药
(603139)
| 流通市值：13.92亿 | | | 总市值：13.92亿 |
| 流通股本：9988.00万 | | | 总股本：9988.00万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 127,367,068.27 | 672,960,241.75 | 472,228,266.33 | 269,296,817.15 |
| 营业收入 | 127,367,068.27 | 672,960,241.75 | 472,228,266.33 | 269,296,817.15 |
| 二、营业总成本 | 133,377,175.4 | 685,241,049.88 | 470,567,191.27 | 261,293,980.78 |
| 营业成本 | 85,992,349.81 | 483,748,383.27 | 333,306,342.64 | 179,122,553.73 |
| 税金及附加 | 3,505,313.33 | 5,304,781.55 | 3,307,292.38 | 1,934,112.71 |
| 销售费用 | 20,621,173.43 | 121,683,999.74 | 86,837,266.2 | 56,455,212.91 |
| 管理费用 | 14,286,017.41 | 45,230,599.63 | 30,134,681.79 | 18,755,383.97 |
| 研发费用 | 1,824,618.48 | 10,980,089.51 | 7,483,361.02 | 4,278,187.86 |
| 财务费用 | 7,147,702.94 | 18,293,196.18 | 9,498,247.25 | 748,529.61 |
| 其中:利息费用 | 7,820,156.66 | 23,461,102.82 | 14,320,745.85 | 4,124,765.83 |
| 其中:利息收入 | 781,968.27 | 5,324,465.38 | 5,129,427.32 | 3,455,886.67 |
| 加:公允价值变动收益 | - | -101,078.53 | -100,737.5 | -28,679 |
| 加:投资收益 | 576,639.86 | -28,643,865.66 | 1,035,092.5 | -1,269,802.53 |
| 资产处置收益 | -3,653.83 | 95,208.27 | 72,230.74 | 72,230.74 |
| 资产减值损失(新) | -37,055.92 | -20,744,576.31 | 2,370,062.37 | 2,151,812.34 |
| 信用减值损失(新) | 1,560,111.06 | -3,828,067.83 | -3,251,451.6 | 2,314,459.34 |
| 其他收益 | 2,689,010.39 | 3,700,631.69 | 1,020,316.8 | 481,237.51 |
| 营业利润平衡项目 | 0.01 | 0 | 0 | 0 |
| 四、营业利润 | -1,225,055.56 | -61,802,556.5 | 2,806,588.37 | 11,724,094.77 |
| 加:营业外收入 | 73,455.14 | 4,839,652.13 | 41,652.03 | 25,383.68 |
| 减:营业外支出 | 437,091.27 | 980,406.89 | 127,927.23 | 115,112.31 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -1,588,691.69 | -57,943,311.26 | 2,720,313.17 | 11,634,366.14 |
| 减:所得税费用 | 894,298.91 | -7,168,114.89 | 1,614,373.41 | 2,706,438.06 |
| 六、净利润 | -2,482,990.6 | -50,775,196.37 | 1,105,939.76 | 8,927,928.07 |
| 持续经营净利润 | -2,482,990.6 | -50,775,196.37 | 1,105,939.76 | 8,927,928.07 |
| 归属于母公司股东的净利润 | 1,086,299.01 | -26,158,640.74 | 9,221,645.63 | 12,599,138.31 |
| 少数股东损益 | -3,569,289.61 | -24,616,555.63 | -8,115,705.87 | -3,671,210.24 |
| (一)基本每股收益 | 0.01 | -0.26 | 0.09 | 0.13 |
| (二)稀释每股收益 | 0.01 | -0.26 | 0.09 | 0.13 |
| 八、其他综合收益 | - | 1,890,974.41 | - | - |
| 归属于母公司股东的其他综合收益 | - | 1,890,974.41 | - | - |
| 九、综合收益总额 | -2,482,990.6 | -48,884,221.96 | 1,105,939.76 | 8,927,928.07 |
| 归属于母公司股东的综合收益总额 | 1,086,299.01 | -24,267,666.33 | 9,221,645.63 | 12,599,138.31 |
| 归属于少数股东的综合收益总额 | -3,569,289.61 | -24,616,555.63 | -8,115,705.87 | -3,671,210.24 |
| 公告日期 | 2024-04-27 | 2024-04-27 | 2023-10-28 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |